AMCP Nexus 2023
Data Supporting Drug Price Hikes Deemed Faulty
The Institute for Clinical and Economic Review (ICER) rejects nearly all (97%) evidence submitted by manufacturers ...
FEBRUARY 29, 2024

Diabetes Deprescribing Saves Millions
A pharmacist-led program to discontinue duplicate incretin therapy with GLP-1 agonists and DPP-4 inhibitors for ...
FEBRUARY 29, 2024

A Record Pace Seen for 2023 Specialty Approvals
The FDA appears to be making up for lost time after the COVID-19 pandemic. The agency is on schedule to approve 51 ...
DECEMBER 4, 2023

NASH: An Interesting Space to Watch
Dr. Aimee Tharaldson, a keynote speaker at AMCP Nexus 2023, spoke with us about the pipeline for nonalcoholic ...
OCTOBER 20, 2023

Non-White Part D Beneficiaries and Low-Income Subsidy Recipients to Be Most Affected by IRA Spending Cap
Non-white Medicare Part D beneficiaries are among those who will be most affected by a $2,000 out-of-pocket ...
OCTOBER 19, 2023

Healthcare Bills Suspended in the House
For now, at least, legislation is at a standstill until a new Speaker of the House is chosen.
OCTOBER 18, 2023

4 Case Studies Highlight AI’s Role in Improving Pharmacy Benefit Performance
Artificial intelligence and machine learning can flag claims errors, prevent fraud, waste and abuse and streamline ...
OCTOBER 18, 2023

AMCP Panel: Biosimilars to See Another Bump by 2025
The year 2023 was big for biosimilars, which saw eight such products added to the market for adalimumab (Humira, ...
OCTOBER 18, 2023
